The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas

Anti-Cancer Drugs

Volumn 13, Issue 9, 2002, Pages 907-913

  Eucker, Jan ^a   Schille, Claudia ^a   Schmid, Peter ^a   Jakob, Christian ^a   Schetelig, Johannes ^a   Kingreen, Dorothea ^a   Mergenthaler, Hans Günther ^a   Huhn, Dieter ^a   Possinger, Kurt ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic lymphocytic leukemia; Cyclophosphamide; Fludarabine; Immunosuppression; Non Hodgkin's lymphoma; Purine analogs

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; DRUG DERIVATIVE; VIDARABINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE COUNT; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; CD4 CD8 RATIO; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-CD8 RATIO; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; REMISSION INDUCTION; VIDARABINE;

EID: 0036813369     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200210000-00002     Document Type: Article

References (23)

1. Zinzani PL, Magagnoli M, Moretti L, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: An encouraging experience in 29 patients. Haematologica 1999; 84: 1002-6.
2. Solal-Céligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adultes. J Clin Oncol 1996; 14: 514-9.
3. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-71.
4. Frewin R, Turner B, Tighe M, Davies S, Rule S, Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999; 104: 612-3.
5. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine and cyclophosphamide in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-43.
6. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effect of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 2000; 14: 379-88.
7. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M. Combined therapy with fludarabine and cyclophosphamid in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 1997; 59: 327-8.
8. Moretta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268-70.
9. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-20.
10. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342-8.
11. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsered working group guidelines for chronic lymphocytic leukemia. Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.
13. Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymph 1995; 18: 485-92.
14. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-8.
15. Flinn W, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71-5.
16. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 59-64.
17. Hochster S, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long term follow-up - A report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000; 18: 987-94.
18. Santini G, Nati S, Spriano M, et al. Fludarabine in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282-6.
19. Hochster H, Weller E, Kuzel T, Frankel S, Horning S. Increased mortality associated with higher dose cyclophosphamide plus fludarabine (CF) in advanced stage indolent lymphoma patients treated on E1496, an Eastern Cooperative Oncology Group (ECOG) and CALGB study. Proc Am Soc Clin Oncol 2002; 21: 282a.
20. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-66.
21. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48.
22. Wijerman PW, Gerrits WBJ, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292-6.
23. Sezer O, Schmid P, Hallek M, et al. Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 1999; 78: 475-7.